Latest news and press releases about Orchestra BioMed Holdings, Inc. (OBIO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures.
Price
| Price | $6.01 |
| Market Cap | $360M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 11.92 |
| EV / EBITDA | -5.85 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -125.93% |
| Return on Invested Capital | -56.28% |
| Return on Assets | -51.02% |
| Gross Margin | 99.32% |
| Operating Margin | -181.36% |
| Net Margin | -184.60% |
Related companies: AVTX · CRBU · ENTA · EPRX · IVA · IVVD · PRLD
Explore sector: Healthcare · Biotechnology
More sections of OBIO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks